Literature DB >> 11835452

Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia.

Susan H Fox1, Mark Kellett, A Peter Moore, Alan R Crossman, Jonathan M Brotchie.   

Abstract

Cannabis may have medicinal uses in a variety of diseases. The neural mechanisms underlying dystonia involve abnormalities within the basal ganglia-in particular, overactivity of the lateral globus pallidus (GPl). Cannabinoid receptors are located presynaptically on GABA terminals within the GPi, where their activation reduces GABA reuptake. Cannabinoid receptor stimulation may thus reduce overactivity of the GPl and thereby reduce dystonia. A double-blind, randomised, placebo-controlled, crossover study using the synthetic cannabinoid receptor agonist nabilone in patients with generalised and segmental primary dystonia showed no significant reduction in dystonia following treatment with nabilone. Copyright 2001 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11835452     DOI: 10.1002/mds.1280

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  26 in total

Review 1.  Cannabis in the Treatment of Dystonia, Dyskinesias, and Tics.

Authors:  Barbara S Koppel
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

Review 2.  [The endogenous cannabinoid system. Therapeutic implications for neurologic and psychiatric disorders].

Authors:  U Schneider; J Seifert; M Karst; J Schlimme; K Cimander; K R Müller-Vahl
Journal:  Nervenarzt       Date:  2005-09       Impact factor: 1.214

Review 3.  Cannabinoids and dystonia: an issue yet to be defined.

Authors:  Marcello Mario Mascia; Daniele Carmagnini; Giovanni Defazio
Journal:  Neurol Sci       Date:  2019-12-17       Impact factor: 3.307

Review 4.  Pharmacokinetics and pharmacodynamics of cannabinoids.

Authors:  Franjo Grotenhermen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 5.  Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology.

Authors:  Barbara S Koppel; John C M Brust; Terry Fife; Jeff Bronstein; Sarah Youssof; Gary Gronseth; David Gloss
Journal:  Neurology       Date:  2014-04-29       Impact factor: 9.910

Review 6.  [Therapeutic use of cannabinoids in neurology].

Authors:  P Schwenkreis; M Tegenthoff
Journal:  Schmerz       Date:  2003-10       Impact factor: 1.107

Review 7.  Treatment strategies for dystonia.

Authors:  Leslie J Cloud; H A Jinnah
Journal:  Expert Opin Pharmacother       Date:  2010-01       Impact factor: 3.889

Review 8.  Is cannabidiol the ideal drug to treat non-motor Parkinson's disease symptoms?

Authors:  José Alexandre S Crippa; Jaime E C Hallak; Antônio W Zuardi; Francisco S Guimarães; Vitor Tumas; Rafael G Dos Santos
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-01-31       Impact factor: 5.270

Review 9.  The therapeutic potential of cannabinoids for movement disorders.

Authors:  Benzi Kluger; Piera Triolo; Wallace Jones; Joseph Jankovic
Journal:  Mov Disord       Date:  2015-02-04       Impact factor: 10.338

Review 10.  Cannabinoid-based medicines for neurological disorders--clinical evidence.

Authors:  Stephen Wright
Journal:  Mol Neurobiol       Date:  2007-06-29       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.